Additional Relevant Details The ulcerative proctitis trial is planned to enroll 18 adult patients with Brilacidin administration through retention enema at three different concentrations once daily at bedtime for a 6-week (42-day) period. Endoscopic evaluation of the rectum and mucosa, up to 40 cm from the anal verge, will be performed at screening and at the end of treatment/Day 42 (± 3 days). All endoscopic evaluations (screening and Day 42) will be photographed and videotaped for eventual adjudication by an independent observer (a gastroenterologist) who is blinded to the day of on-treatment endoscopy and the dosage of Brilacidin used. This process of blinded adjudication (assessing overall results) will be performed after the study’s completion and will not delay patient enrollment.